Stock Ratings / Health Care / ETON / financials

INVA (75) GPCR (42) PAHC (68) TYRA (41) ⌘ Pro Terminal →

Eton Pharmaceuticals Inc. (ETON) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$53.67 +3.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $53.92

Eton Pharmaceuticals Inc. (ETON) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.53B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ETON Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ETON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $53.67 (+3.61% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ETON ranks #169 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ETON compare to INVA and GPCR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, INVA (Innoviva Inc.) holds a B grade (75/100 RQD, P/E N/A, ROIC 14.7%, cap $1.54B) and GPCR (Structure Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ETON?

▼

Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $53.92 (+0.46%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 12.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETON)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY ETON SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)

Altman Z-Score 13.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)

20D Institutional Volume Accumulation (±9.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$55.21-8.9% Next Q

Q2 (-2Q)

Grade B-$50.31-0.6% Next Q

Q3 (-1Q)

Grade C+$50.00+7.3% Next Q

Current

Grade C$53.67+0.7% Hist 90D α

Trajectory: B (70) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ETON Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, ETON faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 51.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($56.00) or 200D SMA ($35.71) invalidates the momentum regime and cuts Target Base ($54.64) toward Bear Floor ($42.62).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ETON• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ETON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ETON Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$10.2M (12.7% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $31.6M

FY24

Rev $39.0M

FY25

Rev $80.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$80.0M	53.5%	-1.1%	-$4.6M	$10.2M	-3%
FY 2024	$39.0M	60%	-6.7%	-$3.8M	$943.0K	-5.2%
FY 2023	$31.6M	53.5%	-3.8%	-$936.0K	$6.8M	-0.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ETON)

✓Walkthrough of ETON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ETON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +122.51%🛡️ HOLDING TREND SUPPORT

2026-10-30O $53.33H $53.67L $51.89C $53.67VOL 335.7K

RES: $71.01SUP: $50.10SMA50: $56.00SMA200: $35.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETON Butterfly Map → + Track ETON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +104.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ETON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ETON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETON)

Health Care Rank #169 of 1016 ⚔️ INVA vs ETON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETON vs. INVA, GPCR, PAHC, TYRA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eton Pharmaceuticals Inc. (ETON) ranks #169 by composite RQD confidence (62/100, grade C) and #303 by equity capitalization ($1.53B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with ETON at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ETON ACTIVE Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	Benchmark Subject
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-eton →
GPCR Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-eton →
PAHC Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	/pahc-vs-eton →
TYRA Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-eton →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001710340

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported GAAP revenue of $80.0M (+104.9% vs. FY2024 revenue of $39.0M , and +152.7% cumulative change since FY2023) , GAAP net income of -$4.6M, operating cash flow of $10.5M, and free cash flow of $10.2M (+980.7% YoY). On the balance sheet, ETON closed FY2025 with $92.1M in total assets against $21.8M in total debt (Altman Z-Score: 13.37, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$80.0M	-$4.6M	$10.5M	$10.2M	$92.1M	$21.8M
FY2024 (FY)	2024-12-31	$39.0M	-$3.8M	$969.0K	$943.0K	$76.1M	$29.8M
FY2023 (FY)	2023-12-31	$31.6M	-$936.0K	$6.8M	$6.8M	—	—

3. ETON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ETON compare to INVA and GPCR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ETON?

Where is ETON trading relative to its 50-day, 200-day, and 52-week technical levels?

ETON last traded at $53.67 (+3.61% on volume of 369,485 shares), positioning the stock -4.16% below its 50-day simple moving average ($56.00) and +50.29% above its 200-day simple moving average ($35.71). Across its 52-week range of $14.27 to $66.37, ETON sits at the 75.6% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($48.41 to $58.93).